4/6/2023 | PV | Immunogen enters $175 million two-tranche term loan with Pharmakon
|
5/6/2019 | CV | Market Commentary: Convertibles firm in quiet trade as equities slide in early action; Tesla underperforms
|
5/6/2019 | CV | Market Commentary: Morning Commentary: Convertibles quiet as equities slide; Tesla bonds little changed
|
1/9/2018 | CV | Market Commentary: Wheeler to price add on to 8.75% preferreds; Insulet in demand; GoPro holders hold on
|
10/12/2017 | CV | Market Commentary: Caesars Entertainment, Intel convertibles active in trading; ImmunoGen bonds, stock soften
|
9/26/2017 | CVLM | ImmunoGen swaps out another $12 million 4.5% convertibles for stock
|
9/12/2017 | CVLM | ImmunoGen swaps out $84.9 million of 4.5% convertibles for stock
|
9/1/2017 | CVLM | ImmunoGen to exchange $76.4 million of 4.5% convertibles for stock
|
6/15/2016 | PP | Market Commentary: New ImmunoGen bond ends flat on debut; Dynegy launches $400 million of units; Par Pacific on tap
|
6/15/2016 | CV | Market Commentary: New ImmunoGen bond ends flat on debut; Dynegy launches $400 million of units; Par Pacific on tap
|
6/15/2016 | CV | Market Commentary: Morning Commentary: New ImmunoGen edges up on an outright basis; Dynegy launches $400 million deal
|
6/15/2016 | CV | New Issue: ImmunoGen prices $100 million five-year convertibles to yield 4.5%, up 20%
|
6/14/2016 | PP | Market Commentary: ImmunoGen shares hammered after deal launch; LinkedIn settles in; Twitter remains active
|
6/14/2016 | CV | Market Commentary: ImmunoGen shares hammered after deal launch; LinkedIn settles in; Twitter remains active
|
6/14/2016 | CV | Market Commentary: Morning Commentary: ImmunoGen shares hammered; deal looks cheap; Twitter remains active
|
6/13/2016 | CV | ImmunoGen to price $100 million five-year convertibles to yield 4%-4.5%, up 20%-25%
|
5/19/2011 | CVHYPF | ImmunoGen files automatic shelf covering stock, preferreds and debt
|
4/9/2010 | CVHYPF | ImmunoGen files $125 million shelf covering stock, preferreds, debt
|
7/23/2009 | SS | Market Commentary: Bristol-Myers' buy narrows drug field; Noven tender opens; TransAlta offer considered risky
|
6/24/2008 | PP | New Issue: ImmunoGen gives more details on $25 million direct offering of shares
|
6/23/2008 | PP | New Issue: ImmunoGen pockets $24.96 million from direct offering of shares
|
6/23/2008 | PP | Market Commentary: Siga secures $8 million equity line; Playfair, Allon, Enhanced Oil plan offerings; ImmunoGen sells stock
|
11/16/2006 | BT | ImmunoGen kept at sector perform by RBC
|
11/3/2006 | BT | ImmunoGen maintained at sector perform by RBC
|
8/31/2006 | BT | Market Commentary: Genta off 15.5%; EpiCept off on PIPE; AnorMED steady; Diomed gains 28%; ImmunoGen higher
|
8/31/2006 | BT | ImmunoGen, Sanofi-Aventis extend cancer drug research collaboration
|
8/31/2006 | BT | ImmunoGen kept at sector perform by RBC
|
8/11/2006 | BT | ImmunoGen rated at sector perform by RBC
|
7/11/2006 | BT | ImmunoGen licenses TAP technology rights to Biotest
|
5/4/2006 | BT | Market Commentary: Bausch & Lomb stock sinks after buyback offering to avoid default; ImmunoGen stock up on earnings
|
4/3/2006 | BT | ImmunoGen says TAP compound is stable while circulating in bloodstream
|
3/30/2006 | BT | ImmunoGen, Millennium extend agreement for tumor-activated prodrug
|
2/3/2006 | BT | Market Commentary: DOV rises; ImmunoGen tumbles; OccuLogix, TLC-Vision plunge; Sirna spikes; CryoCor crumbles
|
1/31/2006 | BT | ImmunoGen receives $2 million milestone payment from Genentech
|
12/13/2005 | BT | Genentech signs up for fourth TAP license with ImmunoGen
|
11/14/2005 | BT | ImmunoGen's BB-10901 shows evidence of effectiveness against cancer in phase 1 trial
|
8/31/2005 | BT | ImmunoGen gets $18.2 million in financing on extended research collaboration with Sanofi-Aventis
|
8/31/2005 | BT | Market Commentary: MedImmune shoots up over 10%; Chiron little changed; Glaxo gains on U.S. flu shot OK; Oscient flat
|
7/26/2005 | BT | Market Commentary: Glaxo pact helps Human Genome; Mylan, Impax up with Teva, Ivax; Elan, Biogen up on Tysabri plans
|